Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced the formation of its Parkinson''s Disease Scientific Advisory Board (SAB), featuring some of the leading medical researchers in neurology. The SAB actively will collaborate with Rexahn on the clinical development strategy for its CNS drug candidate, Serdaxin®.
Chairing the SAB is Dr. William Weiner, Director of the Maryland Parkinson''s Disease and Movement Disorders Center, and Professor and Chair of the Department of Neurology at the University of Maryland School of Medicine. Dr. Weiner is a recognized pioneer and key opinion leader in Neurology. He has been involved in Parkinson''s disease clinical research for over 40 years and has been involved in the development of all the major therapeutic agents used to treat this disease. Dr. Weiner has also published over 200 peer reviewed articles and 20 textbooks related to Parkinson''s disease and related disorders.
Commenting on the newly formed SAB, Dr. Weiner said, "With Serdaxin, Rexahn is developing a promising therapeutic for Parkinson''s disease, a condition in great need of effective treatment options. I am excited to help contribute to the design of Serdaxin''s clinical trials and ultimately to help guide this promising drug into the clinic, where it may one day help treat patients suffering from this debilitating illness."
Joining Dr. Weiner are three additional leading neurology medical experts, including:
Kenneth Marek, MD, President and Senior Scientist, Institute for Neurodegenerative Disorders, New Haven, CT. Dr. Marek serves on the scientific advisory board of the Michael J Fox Foundation. He was a co-founder and continues to lead the AMADEUS consortium, an international SPECT imaging consortium for multi-center neuroimaging in clinical studies. He has served on the executive committee of the Parkinson Study Group. He was also a co- founder of Molecular NeuroImaging, LLC, a company providing clinical neuroimaging research services.
Andrew Feigin, MD, Professor, Departments of Molecular Medicine and Neurology At Hofstra University School of Medicine in Partnership with the North Shore - LIJ Health System. Dr. Feigin has 18 years experience in the design and conduct of clinical trials for Parkinson''s disease.
Fernando Pagan, MD, Associate Professor of Neurology, Co-Director of Movement Disorders Program, Medical Director of National Parkinson Foundation Center of Excellence at Georgetown University Hospital (GUH). He is the fellowship director for the clinical research fellowship in movement disorders at GUH. His areas of specialty include Parkinson''s disease, parkinsonism and other related disorders, ataxia, essential oftremor, dystonia and tics.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.
Safe Harbor
This press release contains forward-looking statements. Rexahn''s actual results may differ materially from anticipated results, and expectations expressed in these forward-looking statements, as a result of certain risks and uncertainties, including Rexahn''s lack of profitability, and the need for additional capital to operate its business to develop its product candidates; the risk that Rexahn''s development efforts relating to its product candidates may not be successful; the possibility of being unable to obtain regulatory approval of Rexahn''s product candidates; the risk that the results of clinical trials may not be completed on time or support Rexahn''s claims; demand for and market acceptance of Rexahn''s drug candidates; Rexahn''s reliance on third party researchers and manufacturers to develop its product candidates; Rexahn''s ability to develop and obtain protection of its intellectual property; and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission. Rexahn assumes no obligation to update these forward-looking statements.
Contacts:
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
or
Base
Pair Communications
Constantine Theodoropulos, 617-401-3116
constantine@basepaircomm.com
